Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | TNKS | O95271 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL103894 | 0.80 | HTR2C (0.53) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL19865160 | 0.77 | L3MBTL1 (0.53) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL24386932 | 0.77 | HTR2C (0.50) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL5477688 | 0.77 | NUDT1 (0.55) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL5405262 | 0.73 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1 | |
| SCHEMBL2273731 | 0.73 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1 | |
| SCHEMBL24529236 | 0.73 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL24529479 | 0.73 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL104884 | 0.73 | HTR2C (0.47) | HTR2CL3MBTL1NUDT1TNKS | |
| SCHEMBL1934651 | 0.73 | HTR2C (0.50) | HTR2CL3MBTL1NUDT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012080234-A1 | SUBSTITUTED 6-IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |
| WO-2012080228-A1 | 6-THIO-SUBSTITUTED IMIDAZOPYRAZINES FOR USE AS MPS-1 AND TKK INHIBITORS IN THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-06-21 | — | — | WO | disclosed |